<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01534273</url>
  </required_header>
  <id_info>
    <org_study_id>14464</org_study_id>
    <secondary_id>I4O-MC-BACJ</secondary_id>
    <nct_id>NCT01534273</nct_id>
  </id_info>
  <brief_title>A Study of LY2886721 in Healthy Participants</brief_title>
  <official_title>Single- and Multiple-Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY2886721 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this phase I study in healthy participants will be to evaluate the safety and
      tolerability of LY2886721 single and multiple doses, how the body handles the drug and the
      drug's effect on the body.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with clinically significant effects</measure>
    <time_frame>Predose up to Day 23</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Plasma maximum observed concentration at steady state (Cmax,ss) of LY2886721</measure>
    <time_frame>Predose up to Day 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Plasma area under the concentration versus time curve (AUC) of LY2886721</measure>
    <time_frame>Predose up to Day 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cerebrospinal fluid (CSF) amyloid 1-40 concentration at Day 15</measure>
    <time_frame>Baseline, Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cerebrospinal fluid (CSF) amyloid 1-40 concentration at 24 hours post-dose</measure>
    <time_frame>Baseline, 24 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single oral dose and/or once daily oral dosing for 14 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>35 mg LY2886721</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily oral dosing for 14 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>70 mg LY2886721</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose followed by once daily oral dosing for 14 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>140 mg LY2886721</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2886721</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>35 mg LY2886721</arm_group_label>
    <arm_group_label>70 mg LY2886721</arm_group_label>
    <arm_group_label>140 mg LY2886721</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men and non-childbearing potential women

          -  Body mass index between 18.0-32.0 kg/m^2

          -  Are reliable and willing to make yourself available for the duration of the study and
             are willing to follow study procedures and research unit policies

        Exclusion Criteria:

          -  Taking over-the-counter or prescription medication with the exception of vitamins or
             minerals

          -  Smoke more than 10 cigarettes per day

          -  Drink more than 5 cups of caffeine containing beverages (e.g., coffee, tea) per day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri, 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2012</study_first_submitted>
  <study_first_submitted_qc>February 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2012</study_first_posted>
  <last_update_submitted>August 9, 2012</last_update_submitted>
  <last_update_submitted_qc>August 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mild Cognitive Impairment</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

